Regeneron to share progress of novel combination therapies in oncology at esmo io

First dose-escalation results for regn5668 (muc16xcd28), a costimulatory bispecific, in combination with libtayo ® (cemiplimab) showed encouraging initial activity in patients with recurrent ovarian cancer
REGN Ratings Summary
REGN Quant Ranking